emerg
infecti
diseas
human
often
caus
respiratori
virus
pandem
avian
influenza
virus
novel
coronavirus
microbiolog
test
respiratori
virus
import
patient
manag
infect
control
epidemiolog
studi
nasopharyng
specimen
frequent
test
sensit
suboptim
studi
evalu
increment
benefit
test
respiratori
virus
expector
saliva
use
molecular
assay
total
hospit
adult
patient
suspect
respiratori
infect
includ
expector
saliva
collect
without
use
special
devic
first
cohort
patient
whose
nasopharyng
aspir
npa
test
posit
respiratori
virus
routin
test
viral
load
measur
use
quantit
revers
transcript
pcr
seventeen
percent
patient
higher
viral
load
saliva
npa
second
cohort
consist
patient
whose
npa
test
neg
respiratori
virus
use
direct
immunofluoresc
assay
npa
saliva
specimen
addit
test
use
multiplex
pcr
patient
concord
rate
multiplex
pcr
npa
saliva
multiplex
pcr
detect
virus
saliva
sampl
patient
nine
least
one
viru
detect
npa
decis
antivir
isol
precaut
would
affect
salivari
test
six
patient
although
npa
high
viral
load
remain
specimen
choic
patient
respiratori
viru
infect
supplementari
molecular
test
saliva
improv
clinic
manag
patient
virus
play
import
role
respiratori
tract
infect
recent
sever
novel
respiratori
virus
emerg
includ
pandem
influenza
viru
avian
influenza
virus
middl
east
respiratori
syndrom
mer
coronaviru
novel
avian
influenza
virus
mer
coronaviru
associ
high
mortal
rate
prompt
accur
detect
respiratori
virus
import
guid
antivir
treatment
influenza
viru
infect
earlier
administr
neuraminidas
inhibitor
associ
faster
resolut
symptom
random
clinic
trial
improv
surviv
retrospect
studi
hyperimmun
intraven
immunoglobulin
confer
surviv
benefit
sever
influenza
administ
within
day
symptom
onset
antibiot
usag
reduc
respiratori
viru
detect
without
evid
bacteri
infect
earli
detect
also
import
infect
control
public
health
measur
nasopharyng
aspir
npa
nasopharyng
swab
np
includ
flock
swab
nasal
throat
swabswash
recommend
upper
respiratori
tract
specimen
type
diagnost
test
respiratori
virus
nasopharyng
specimen
usual
consid
highest
detect
rate
respiratori
virus
nasopharyng
specimen
often
use
specimen
type
routin
clinic
practic
mani
surveil
studi
detect
respiratori
virus
howev
studi
test
multipl
specimen
type
nasopharyng
specimen
found
neg
patient
respiratori
viru
infect
sputum
lower
respiratori
tract
specimen
may
contain
higher
viral
load
patient
improv
detect
virus
jeong
et
al
show
nasopharyng
swab
neg
adult
patient
sputum
posit
respiratori
virus
howev
mani
patient
sputum
product
expector
good
qualiti
sputum
addit
collect
tracheal
bronchial
specimen
involv
invas
procedur
associ
signific
discomfort
risk
patient
pose
risk
healthcar
worker
saliva
easili
provid
patient
without
invas
procedur
howev
saliva
rare
use
detect
respiratori
virus
gener
consid
inferior
sensit
compar
respiratori
tract
specimen
salivari
histatin
human
neutrophil
defensin
saliva
shown
neutral
influenza
viru
moreov
saliva
suitabl
specimen
type
direct
immunofluoresc
assay
dfa
contain
suffici
amount
infect
respiratori
epitheli
cell
recent
renew
interest
use
saliva
detect
respiratori
virus
molecular
assay
studi
show
detect
rate
respiratori
virus
actual
higher
saliva
nasopharyng
specimen
howev
studi
conduct
either
children
among
adult
patient
mild
symptom
requir
hospit
studi
evalu
detect
influenza
viru
furthermor
mani
studi
use
special
collect
devic
usual
avail
hospit
util
saliva
detect
respiratori
virus
among
hospit
adult
patient
comprehens
studi
current
studi
sought
evalu
benefit
test
expector
saliva
addit
npa
among
adult
patient
hospit
suspect
respiratori
tract
infect
aim
first
part
studi
assess
differ
viral
load
npa
saliva
use
quantit
pcr
revers
transcript
rtpcr
aim
second
part
studi
evalu
increment
benefit
test
saliva
addit
npa
use
commerci
avail
molecular
assay
current
studi
design
enabl
easi
applic
saliva
specimen
collect
method
clinic
set
ask
studi
particip
provid
saliva
specimen
simpl
expector
steril
bottl
without
use
special
collect
devic
studi
prospect
studi
conduct
march
februari
queen
mari
hospit
teach
hospit
hong
kong
bed
studi
approv
institut
review
board
univers
hong
konghospit
author
hong
kong
west
cluster
written
inform
consent
obtain
studi
particip
patient
elig
recruit
hospit
adult
patient
age
year
suspect
respiratori
tract
infect
npa
sampl
obtain
respiratori
viru
test
saliva
specimen
collect
enrol
patient
result
routin
clinic
test
respiratori
virus
clinic
microbiolog
laboratori
queen
mari
hospit
known
therefor
patient
saliva
specimen
alway
collect
npa
specimen
patient
exclud
studi
discharg
hospit
enrol
unabl
provid
saliva
specimen
refus
unabl
provid
written
inform
consent
first
part
studi
consist
patient
whose
npa
sampl
test
posit
respiratori
virus
dfa
influenza
viru
gene
realtim
rtpcr
routin
respiratori
viru
test
clinic
microbiolog
laboratori
figur
viral
load
determin
npa
saliva
sampl
use
quantit
rtpcr
qrtpcr
first
phase
march
june
patient
test
posit
influenza
viru
includ
second
phase
june
februari
patient
test
posit
respiratori
virus
includ
second
part
studi
consist
patient
whose
npa
specimen
either
test
neg
respiratori
virus
dfa
insuffici
nasopharyng
columnar
epitheli
cell
npc
npa
sampl
dfa
routin
clinic
test
figur
insuffici
npc
defin
npc
entir
well
multiplex
pcr
use
test
respiratori
virus
npa
saliva
sampl
patient
data
concern
demograph
underli
diseas
clinic
find
radiolog
chang
record
predesign
databas
charlson
comorbid
score
calcul
pneumonia
defin
radiolog
evid
new
increas
pulmonari
infiltr
chest
radiograph
least
one
follow
symptom
cough
without
sputum
product
dyspnea
tachypnea
pleurit
chest
pain
plu
one
auscultatori
find
one
sign
infect
core
bodi
temperatur
shiver
leukocyt
count
describ
previous
routin
respiratori
viru
test
clinic
microbiolog
laboratori
npa
sampl
collect
viral
transport
medium
vtm
describ
previous
routin
test
respiratori
virus
perform
use
antigen
detect
dfa
ultra
dfa
respiratori
viru
screen
identif
kit
diagnost
hybrid
inc
quidel
san
diego
ca
usa
includ
influenza
viru
influenza
b
viru
parainfluenza
virus
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
adenoviru
march
april
peak
influenza
viru
season
hong
kong
realtim
rtpcr
influenza
viru
gene
perform
patient
admit
gener
medic
ward
describ
previous
period
dfa
perform
npa
sampl
test
posit
influenza
viru
use
rtpcr
patient
instruct
expector
saliva
steril
contain
ml
vtm
ad
contain
microbiolog
laboratori
volum
saliva
rang
ml
figur
studi
design
nasopharyng
aspir
npa
quantit
pcr
revers
transcript
qrtpcr
routin
clinic
test
perform
use
antigen
detect
dfa
includ
influenza
b
virus
parainfluenza
viru
type
respiratori
syncyti
viru
human
metapneumoviru
adenoviru
march
april
peak
influenza
viru
season
monoplex
realtim
rtpcr
influenza
gene
perform
patient
admit
gener
medic
ward
b
patient
whose
npa
specimen
either
test
neg
respiratori
virus
dfa
insuffici
npc
dfa
routin
clinic
test
insuffici
npc
defin
npc
entir
well
quantit
rtpcr
respiratori
virus
total
nucleic
acid
tna
extract
perform
use
easymag
instrument
biomerieux
boxtel
netherland
describ
previous
npa
saliva
specimen
vtm
mix
lyse
buffer
extract
nucleic
acid
recov
use
elut
buffer
qrtpcr
influenza
viru
detect
carri
use
superscript
iii
platinum
onestep
rtpcr
reagent
invitrogen
carlsbad
ca
usa
describ
previous
modif
reagent
mixtur
contain
reaction
mix
superscript
iii
rtplatinum
taq
mix
rox
reagent
forward
revers
primer
probe
tna
templat
thermal
cycl
condit
min
revers
transcript
min
rt
inactivationiniti
denatur
cycl
reaction
perform
use
steponeplu
realtim
pcr
system
appli
biosystem
foster
citi
ca
usa
qrtpcr
detect
influenza
b
viru
parainfluenza
virus
hmpv
respiratori
syncyti
viru
carri
use
agpathid
onestep
rtpcr
reagent
appli
biosystem
reagent
mixtur
contain
rtpcr
buffer
rtpcr
enzym
mix
forward
revers
primer
probe
tna
templat
thermal
cycl
condit
min
revers
transcript
min
rt
inactivationiniti
denatur
cycl
reaction
perform
use
lightcycl
realtim
pcr
system
roch
basel
switzerland
primer
probe
sequenc
shown
tabl
multiplex
pcr
respiratori
virus
perform
use
nxtag
respiratori
pathogen
panel
ivd
luminex
austin
tx
usa
accord
manufactur
instruct
respiratori
virus
detect
assay
includ
influenza
viru
influenza
b
viru
rsv
b
enterovirusrhinoviru
evrv
parainfluenza
virus
hmpv
adenoviru
coronavirus
human
bocaviru
extract
tna
ad
preplat
lyophil
bead
reagent
reaction
amplifi
via
rtpcr
reaction
product
underw
bead
hybrid
within
seal
reaction
well
hybrid
tag
bead
sort
read
magpix
instrument
signal
analyz
use
nxtag
respiratori
pathogen
panel
assay
file
synct
softwar
luminex
austin
tx
usa
mannwhitney
utest
fisher
exact
test
use
comparison
continu
categor
variabl
respect
wilcoxon
matchedpair
sign
rank
test
use
comparison
npa
saliva
viral
load
correl
viral
load
npa
saliva
specimen
determin
use
spearman
correl
coeffici
mcnemar
test
use
compar
posit
rate
npa
saliva
specimen
logtransform
data
use
statist
calcul
viral
load
statist
analysi
perform
use
spss
ibm
corp
armonk
ny
usa
graphpad
prism
graphpad
softwar
la
jolla
ca
usa
first
cohort
comparison
viral
load
npa
saliva
sampl
first
cohort
consist
patient
known
respiratori
viru
infect
tabl
supplementari
tabl
median
age
year
rang
year
median
charlson
comorbid
score
forti
patient
pneumonia
two
patient
requir
admiss
intens
care
unit
two
patient
die
saliva
specimen
collect
day
collect
npa
sampl
among
first
cohort
patient
respiratori
viru
detect
npa
sampl
routin
clinic
test
qrtpcr
viru
posit
npa
specimen
patient
saliva
specimen
patient
tabl
among
patient
test
posit
influenza
viru
npa
specimen
patient
test
influenza
viru
gene
rtpcr
routin
clinic
servic
saliva
sampl
posit
qrtpcr
patient
although
median
viral
load
significantli
greater
npa
saliva
sampl
vs
log
copi
per
ml
patient
higher
viral
load
saliva
npa
sampl
figur
signific
correl
found
viral
load
npa
saliva
p
among
patient
influenza
influenza
b
viru
infect
signific
differ
found
median
salivari
viral
load
detect
respiratori
virus
saliva
kkw
et
al
patient
saliva
collect
saliva
collect
oseltamivir
treatment
vs
log
copi
per
ml
p
figur
signific
differ
median
viral
load
detect
saliva
specimen
patient
pneumonia
without
pneumonia
vs
log
copi
per
ml
p
figur
respiratori
virus
detect
saliva
specimen
patient
whose
npa
specimen
test
neg
nxtag
respiratori
pathogen
panel
includ
three
patient
influenza
viru
two
patient
hmpv
two
patient
evrv
one
patient
coronaviru
tabl
patient
whose
npa
specimen
test
posit
nxtag
respiratori
pathogen
panel
one
patient
addit
viru
speci
detect
saliva
patient
tabl
potenti
chang
antivir
treatment
infect
control
practic
would
possibl
six
nine
patient
addit
virus
detect
saliva
three
patient
influenza
viru
infect
could
given
neuraminidas
inhibitor
wherea
three
patient
hmpv
place
contact
precaut
tabl
detect
virus
use
quantit
realtim
revers
transcript
pcr
first
cohort
patient
greatli
enhanc
sensit
detect
respiratori
virus
howev
studi
report
evalu
specimen
type
improv
detect
rate
studi
evalu
use
saliva
addit
npa
diagnosi
respiratori
viral
infect
two
part
first
part
studi
saliva
higher
viral
load
npa
patient
test
posit
respiratori
virus
dfa
influenza
viru
rtpcr
npa
sampl
second
part
studi
saliva
specimen
test
posit
eight
patient
whose
npa
specimen
test
neg
multiplex
pcr
among
patient
whose
npa
specimen
unsuit
dfa
test
neg
dfa
posit
multiplex
pcr
one
patient
addit
respiratori
viru
detect
saliva
specimen
use
multiplex
pcr
importantli
chang
antivir
treatment
isol
precaut
could
occur
six
patient
addit
respiratori
virus
detect
saliva
previou
studi
saliva
obtain
use
dropper
special
spong
stick
advantag
use
devic
amount
saliva
standard
saliva
less
like
contamin
sputum
howev
collect
devic
usual
avail
gener
medic
ward
set
furthermor
collect
saliva
devic
requir
help
healthcar
worker
present
studi
simpli
ask
patient
expector
saliva
standard
steril
sputum
contain
use
routin
hospit
special
collect
devic
requir
use
expector
saliva
implement
easili
daili
clinic
practic
one
possibl
concern
expector
saliva
may
mix
sputum
may
contain
higher
viral
load
saliva
howev
aim
use
saliva
increas
detect
rate
perceiv
limit
actual
favor
reallif
clinic
practic
test
npa
saliva
simultan
costli
costeffect
approach
test
saliva
npa
result
neg
henc
current
studi
mimic
situat
collect
saliva
npa
result
avail
previou
studi
influenza
virus
show
patient
usual
higher
viral
load
npa
upon
hospit
admiss
therefor
saliva
collect
later
may
lower
viral
load
may
result
lower
sensit
detect
although
studi
primarili
design
evalu
increment
benefit
test
saliva
addit
npa
result
provid
insight
potenti
use
test
saliva
alon
among
npaposit
specimen
detect
rate
saliva
first
part
studi
second
part
studi
notabl
detect
rate
respiratori
virus
multiplex
pcr
second
part
studi
slightli
higher
saliva
npa
kim
et
al
also
show
multiplex
pcr
saliva
np
specimen
similar
detect
rate
therefor
use
saliva
alon
may
inferior
use
npa
singl
type
specimen
test
test
saliva
npa
mani
advantag
first
collect
saliva
rather
npa
avoid
patient
discomfort
second
collect
saliva
suitabl
patient
collect
nasopharyng
specimen
contraind
patient
sever
bleed
tendenc
third
patient
provid
saliva
specimen
simpl
instruct
wherea
collect
nasopharyng
specimen
must
perform
healthcar
personnel
approach
would
reduc
delay
specimen
collect
final
collect
saliva
requir
special
infect
control
precaut
perform
clinic
set
standard
precaut
contrast
procedur
collect
nasopharyng
specimen
potenti
aerosolgener
therefor
pose
signific
risk
healthcar
worker
patient
health
author
recommend
nasopharyng
specimen
collect
neg
pressur
isol
room
patient
suspect
mer
coronaviru
novel
influenza
virus
sputum
also
noninvas
specimen
use
detect
respiratori
virus
especi
patient
pneumonia
howev
mani
patient
respiratori
viru
infect
sputum
product
expector
good
qualiti
sputum
contrast
saliva
specimen
obtain
much
easili
sputum
specimen
dfa
routin
use
clinic
set
diagnosi
respiratori
viru
infect
advantag
dfa
includ
rel
low
cost
rapid
result
simultan
detect
multipl
viral
pathogen
howev
sensit
dfa
low
compar
molecular
assay
influenza
pandem
sensit
dfa
rang
dfa
also
low
sensit
influenza
viru
infect
anoth
disadvantag
dfa
suitabl
saliva
specimen
dfa
detect
viral
antigen
present
insid
infect
cell
present
saliva
therefor
avoid
bia
differ
test
use
multiplex
pcr
panel
test
npa
saliva
specimen
although
multiplex
pcr
panel
use
second
cohort
nxtag
respiratori
pathogen
panel
sensit
dfa
lower
sensit
realtim
rtpcr
assay
sensit
nxtag
respiratori
pathogen
panel
rang
compar
realtim
pcr
rtpcr
therefor
patient
respiratori
viru
infect
may
miss
even
npa
saliva
specimen
test
multiplex
pcr
panel
studi
sever
limit
first
saliva
collect
method
suitabl
patient
expector
saliva
patient
unconsci
patient
suction
aspir
saliva
requir
second
first
cohort
evalu
virus
includ
routin
dfa
influenza
viru
rtpcr
import
respiratori
virus
rhinovirus
coronavirus
need
evalu
third
number
specimen
viru
speci
small
compar
differ
sensit
specif
viru
speci
although
viral
load
saliva
lower
viral
load
npa
patient
shown
test
expector
saliva
npa
significantli
improv
detect
respiratori
virus
compar
test
npa
alon
saliva
obtain
patient
suspect
respiratori
viru
infect
neg
test
respiratori
virus
furthermor
saliva
evalu
specimen
type
diagnost
test
novel
respiratori
virus
approach
ultim
lead
improv
manag
patient
prevent
commun
nosocomi
spread
infect
